Kentaro Yamazaki

14.5k total citations · 1 hit paper
278 papers, 3.7k citations indexed

About

Kentaro Yamazaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kentaro Yamazaki has authored 278 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Oncology, 155 papers in Pulmonary and Respiratory Medicine and 45 papers in Surgery. Recurrent topics in Kentaro Yamazaki's work include Colorectal Cancer Treatments and Studies (178 papers), Gastric Cancer Management and Outcomes (103 papers) and Cancer Treatment and Pharmacology (82 papers). Kentaro Yamazaki is often cited by papers focused on Colorectal Cancer Treatments and Studies (178 papers), Gastric Cancer Management and Outcomes (103 papers) and Cancer Treatment and Pharmacology (82 papers). Kentaro Yamazaki collaborates with scholars based in Japan, United States and Belgium. Kentaro Yamazaki's co-authors include Takayuki Yoshino, Atsushi Ohtsu, Narikazu Boku, Seiji Shiotani, Noriyoshi Ohashi, Eric Van Cutsem, Mototsugu Kohno, Kei Muro, Tomohiro Nishina and Rocio García‐Carbonero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Kentaro Yamazaki

256 papers receiving 3.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Takayuki Yoshino, Kentaro Yamazaki et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kentaro Yamazaki Japan	30	2.4k	1.5k	681	629	572	278	3.7k
Carlo Barone Italy	31	2.3k 0.9×	1.4k 0.9×	671 1.0×	461 0.7×	769 1.3×	130	3.6k
Woo Yong Lee South Korea	41	3.4k 1.4×	1.1k 0.7×	1.9k 2.9×	754 1.2×	666 1.2×	231	5.0k
Côme Lepage France	39	3.5k 1.4×	1.5k 1.0×	1.8k 2.6×	993 1.6×	572 1.0×	214	5.3k
Kanwal Raghav United States	33	2.9k 1.2×	1.2k 0.8×	879 1.3×	1.2k 1.9×	628 1.1×	203	4.3k
Filippo Pietrantonio Italy	37	2.9k 1.2×	1.5k 1.0×	1.1k 1.7×	1.2k 1.9×	1.1k 2.0×	298	5.0k
Gianluca Tomasello Italy	33	3.7k 1.5×	1.7k 1.2×	951 1.4×	903 1.4×	885 1.5×	129	5.0k
David R. Fogelman United States	36	3.4k 1.4×	944 0.6×	924 1.4×	623 1.0×	663 1.2×	143	4.3k
Pia Österlund Finland	27	3.0k 1.2×	1.0k 0.7×	492 0.7×	501 0.8×	787 1.4×	96	4.2k
Sylvain Manfrédi France	28	2.3k 1.0×	1.2k 0.8×	1.3k 1.9×	543 0.9×	343 0.6×	117	3.5k
Tadahiro Nozoe Japan	28	1.7k 0.7×	970 0.7×	1.1k 1.7×	245 0.4×	490 0.9×	142	3.1k

Countries citing papers authored by Kentaro Yamazaki

Since Specialization

Citations

This map shows the geographic impact of Kentaro Yamazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kentaro Yamazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kentaro Yamazaki more than expected).

Fields of papers citing papers by Kentaro Yamazaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kentaro Yamazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kentaro Yamazaki. The network helps show where Kentaro Yamazaki may publish in the future.

Co-authorship network of co-authors of Kentaro Yamazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Kentaro Yamazaki. A scholar is included among the top collaborators of Kentaro Yamazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kentaro Yamazaki. Kentaro Yamazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Machida, Nozomu, Takehiro Okumura, Narikazu Boku, et al.. (2025). A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. 131(7). e35807–e35807. 1 indexed citations

Kato, Yoshiyasu, Ryo Ashida, Katsuhisa Ohgi, et al.. (2025). Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. Pancreas. 54(7). e630–e636.

Yamashita, Takashi, et al.. (2024). Neuromuscular electrical stimulation for facial wrinkles and sagging: The 8‐week prospective, split‐face, controlled trial in Asians. Journal of Cosmetic Dermatology. 23(10). 3222–3233. 3 indexed citations

Uetake, Hiroyuki, Kohei Shitara, Takayuki Yoshino, et al.. (2024). Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.. Journal of Clinical Oncology. 42(16_suppl). 3507–3507. 2 indexed citations

Mayanagi, Shuhei, Takahiro Tsushima, Tomoya Yokota, et al.. (2024). Survival outcome of esophagectomy and chemoradiotherapy for resectable esophageal squamous cell carcinoma in patients >75 years of age. Thoracic Cancer. 15(21). 1656–1664. 1 indexed citations

Kito, Yosuke, Hisato Kawakami, Seiichiro Mitani, et al.. (2023). Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The Oncologist. 29(3). e330–e336. 5 indexed citations

Kajiwara, Takeshi, Tomohiro Nishina, Yoshiaki Nakamura, et al.. (2023). Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers. 15(21). 5172–5172. 1 indexed citations

Yamamoto, Noboru, Takafumi Koyama, Toshio Shimizu, et al.. (2023). Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 91(6). 469–480. 6 indexed citations

Yuki, Satoshi, Takeshi Kawakami, Takatsugu Ogata, et al.. (2023). 615P The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer. Annals of Oncology. 34. S441–S442. 1 indexed citations

10.

Kawakami, Takeshi, Toshiki Masuishi, Yasuyuki Kawamoto, et al.. (2022). The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. Cancer Medicine. 11(11). 2184–2192. 1 indexed citations

11.

Moriwaki, Toshikazu, Shota Fukuoka, Toshiki Masuishi, et al.. (2021). Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. Anticancer Research. 41(4). 2203–2207. 2 indexed citations

12.

Hirata, Kenro, Yasuo Hamamoto, Masahiko Ando, et al.. (2020). Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group. BMC Cancer. 20(1). 548–548. 9 indexed citations

13.

Miura, Yuji, Masahiko Ando, Kentaro Yamazaki, et al.. (2020). Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Supportive Care in Cancer. 29(7). 3715–3723. 7 indexed citations

14.

Taniguchi, Hiroya, Takeharu Yamanaka, Daisuke Sakai, et al.. (2020). Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers. 12(7). 1715–1715. 8 indexed citations

15.

Miyo, Masaaki, Takeshi Kato, Takayuki Yoshino, et al.. (2020). Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer. 20(1). 687–687. 8 indexed citations

16.

Ito, Takaaki, Teiichi Sugiura, Yukiyasu Okamura, et al.. (2019). The Safety and Survival Outcome of Hepatectomy with Combined Bile Duct Resection for Colorectal Liver Metastasis. World Journal of Surgery. 44(4). 1231–1243.

17.

Oki, Eiji, Takeshi Kato, Hideaki Bando, et al.. (2018). A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clinical Colorectal Cancer. 17(2). 147–155. 32 indexed citations

18.

Yoshino, Takayuki, Kentaro Yamazaki, Tetsuya Hamaguchi, et al.. (2012). Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.. PubMed. 32(3). 973–9. 6 indexed citations

19.

Taira, Koichi, Narikazu Boku, Akira Fukutomi, et al.. (2008). Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer. Journal of Gastroenterology. 43(11). 875–880. 3 indexed citations

20.

Shiotani, Seiji, Mototsugu Kohno, Noriyoshi Ohashi, et al.. (2003). Non-traumatic postmortem computed tomographic (PMCT) findings of the lung. Forensic Science International. 139(1). 39–48. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact